# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target fr...
BMO Capital analyst Kostas Biliouris maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price ta...
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $29 price tar...
-SEC Filing
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such a...